2020 American Transplant Congress
Comparison of Basiliximab for Induction Therapy in Kidney Transplant Recipients on Post-Operative Days 0 and 4 versus Post-Operative Days 0 and 3
Pharmacy, CHI St. Luke's Health Baylor St. Luke's Medical Center, Houston, TX
*Purpose: Current dosing recommendations for the administration of basiliximab on post-operative days (POD) 0 and 4 stem from two phase 3 renal transplant studies. Limited…2019 American Transplant Congress
PD-1+CD3+CD4-CD8- (Double Negative T-cells) Are Early Responders during Kidney Ischemia Reperfusion Injury and Regulated by Non-Classical MHC Molecules
Johns Hopkins University and School of Medicine, Baltimore, MD
*Purpose: Unconventional T-cells (e.g. Tregs and γδT-cells) are increasingly recognized for their roles in maintaining homeostasis and protecting non-lymphoid tissues against injury/stress. Double negative (DN)…2019 American Transplant Congress
To Each Their Own: Center-Level Variation in Tailoring Induction Immunosuppression to Kidney Transplant Recipients
Johns Hopkins University, Baltimore, MD
*Purpose: Ideally, induction immunosuppression should be selected in a personalized manner. However, there is little knowledge of what clinical factors are considered in this process…2019 American Transplant Congress
Lymphotoxin Signaling Regulates T Cell Lymphatic Trafficking
*Purpose: Lymphotoxin (LT) α1β2 is crucial for lymphatic organ development and orchestration of immune responses. LTα1β2 is preferentially expressed by regulatory T cells (Treg) for…2019 American Transplant Congress
Engineering Regulatory T Cells With TCR-Signaling-Responsive Interleukin 2 Nanoparticles Provides In Situ Suppression Of Alloimmunity
*Purpose: Adoptive cell transfer of regulatory T cells (TReg) has shown great potential in animal models of auto- and alloimmunity. The translation of TReg therapies…2019 American Transplant Congress
Peri-Operative Basiliximab is Not Associated with Post-Transplant Hepatocellular Carcinoma Recurrence in Liver Transplant Recipients
*Purpose: The optimal immunosuppression for liver transplant recipients (LTR) with hepatocellular carcinoma (HCC) is unknown. Basiliximab, an interleukin-2 receptor antagonist (IL-2RA), confers immunosuppression for LTR…2018 American Transplant Congress
Engineering Regulatory T Cells with Interleukin (IL-)2 Nanogel for Improved Alloimmune Suppression
Clinical trials of adoptively transferred regulatory T cells (TRegs) have been hindered by the short lifespan of these transferred TRegs. Systemic injection of low-dose interleukin…2018 American Transplant Congress
TLR2 with TCR Signaling Mobilizes Treg Lymphatic Migration
Background: Regulatory T cells (Treg) express high levels of lymphotoxin (LT) and bind the LT receptor (LTβR) on lymphatic endothelial cells (LEC). This receptor-ligand interaction…2017 American Transplant Congress
Utility of IL-2 Complexes in Promoting Vascularized Composite Allograft Survival.
Vascularized composite allografts (VCA) are a novel, life-enhancing form of transplantation (Tx). The complexity of host immune responses to VCA tissues, especially those involving skin,…2017 American Transplant Congress
Using Basiliximab Does Not Increase De Novo DSA Incidence but Reduces Cytomegalovirus Infections and Neoplastic Complications in Non-Sensitized Kidney Transplant Patients.
Background. In kidney transplantation, de novo donor specific antibodies (dnDSA) are associated with antibody-mediated rejection (AMR) and graft failure. After dnDSA development, 24% of the…
American Transplant Congress abstracts